Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION	
Name		Name	
ID Number		Specialty	
D.O.B.	/MM/DD/YYYY □Male □Female	Address	
Diagnosis		City /State/Zip	
Drug Name Onpattro		Phone: Fax:	
Dose and Quantity		NPI	
Directions		Contact Person	
Date of Service(s)		Contact Person Phone / Ext.	
TEP 1: DISEASE STA	ATE INFORMATION	Thone / Ext.	
Patient We Patient Hei Will the provide	ographic Information: ight:kg ght:ftinches er be administering the medication to the FEP r □ No If No, a prior authorization is not requ	member within the health plan's geographic service area? sired through this process.	
Is this member' ☐ If prin☐ If seco	er's benefit requirements. s FEP coverage primary or secondary coverage nary, continue with question set. ondary, an authorization is not needed throughination of benefit and additional information.	gh this process. Please contact the member's primary coverage for	
☐ Phy☐ Out		filiated ambulatory infusion center. the the name of the infusion center and rationale why the patient testing.	
☐ Polyneu:	ions: patient's diagnosis? ropathy of hereditary transthyretin-mediated (hagnosis (please specify):		
2. Will the par	Will the patient be premedicated to reduce the risk of infusion-related reactions? ☐ Yes ☐ No		
3. Will Onpat	Will Onpattro be administered by a healthcare professional? ☐ Yes ☐ No		
	Does the prescriber agree to supplement the patient with the recommended daily allowance of Vitamin A if indicated? ☐ Yes ☐ No		
	Will this medication be used in combination with Tegsedi (inotersen) or Amvuttra (vutrisiran) for the diagnosis of polyneuropathy caused by hATTR amyloidoisis? Yes No		
6. Has the pat	ient been on Onpattro therapy continuously for	r the last 6 months, excluding samples?	

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)				
Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.				
Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function				
Physician's Nar	ne Physician Signature	Date		
Step 2:	☐ Form Completely Filled Out	□ A441, 4414-		
Checklist	☐ Provide chart notes	☐ Attach test results		
Step 3:	By Fax: BCBSM Specialty Pharmacy Mailbox	By Mail: BCBSM Specialty Pharmacy Program		
Submit	1-877-325-5979	P.O. Box 312320, Detroit, MI 48231-2320		